Last updated: 2026-09-06 09:03:00. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Vir Biotechnology, Inc. (VIR) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $11.39, with a market capitalization of $1.93B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $4.75 to $11.94. This page covers its latest market performance, valuation, price trends and company information.
$1.93B | |
$11.28 | |
$141.01 | |
$4.16 | |
$11.45 | |
963.04K | |
-- | |
-- | |
$11.94 | |
$4.75 | |
-- | |
-- |
Vir Biotechnology, Inc. (VIR) last closed at $11.45 as of 2026-09-04 23:48:00, unchanged from the previous close of $11.45.
During the latest regular trading session, VIR traded between $4.16 and $141.01, with a volume of 963.04K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Vir Biotechnology, Inc. (VIR) moved from $10.77 to $11.39, representing a gain of 5.75% ($0.62).
The stock traded between $11.20 and $11.64 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 2.31 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 92.3%
VIR is currently trading at $11.39, placing it 92.3% of the way from its 52-week low of $4.75 to its 52-week high of $11.94. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer. The company uses its capabilities in antibody discovery and engineering, coupled with its proprietary AI engine dAIsY system, and the PRO-XTEN masking platform, to quickly and effectively discover and optimize potential new medicines. Its clinical development pipeline consists of investigational therapies like Tobevibart + elebsiran targeting the hepatitis delta virus (HDV), preclinical antibody candidates targeting HIV, and VIR-5500, VIR-5818, VIR-5525, and 7 PRO-XTEN programs targeting multiple solid tumors. Currently, the company generates revenue mainly by issuing license rights and through grants.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 367 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Vir Biotechnology, Inc. (VIR) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.